ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast cancer.

Oleg Gluz,Iris Scheffen,Tom Degenhardt,Norbert Marschner,Matthias Christgen,Hans Kreipe,Ulrike Nitz,Ronald E. Kates,Timo Schinkoethe,Monika Graeser,Rachel Wuerstlein,Sherko Kuemmel,Lelia Bauer,Christian Schem,Tanja Fehm,Hans Neubauer,Nadia Harbeck

ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast cancer.

2021

Oleg Gluz
Iris Scheffen
Tom Degenhardt
Norbert Marschner
Matthias Christgen
Hans Kreipe
Ulrike Nitz
Ronald E. Kates
Timo Schinkoethe
Monika Graeser
Rachel Wuerstlein
Sherko Kuemmel
Lelia Bauer
Christian Schem
Tanja Fehm
Hans Neubauer
Nadia Harbeck

TPS598Background: The WSG ADAPT trial program addresses the individualization of (neo)adj. decision-making in EBC. The ADAPT umbrella trial established early predictive molecular surrogate markers ...

Keywords:

Internal medicine
Medicine
personalized therapy
endocrine therapy
Oncology
Adjuvant
open label
Abemaciclib
early breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations